Brief: Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171
17/06/2024 11:16
June 17 (Reuters) - Zymeworks Inc ZYME.O :
* ZYMEWORKS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW
DRUG
APPLICATION FOR ZW171, A NOVEL 2+1 T-CELL TARGETING BISPECIFIC
ANTIBODY FOR MESOTHELIN-EXPRESSING CANCERS
* ZYMEWORKS: TO FILE APPLICATIONS SEEKING REGULATORY
PERMISSION TO
COMMENCE CLINICAL STUDIES FOR ZW171 IN OTHER NON-US
JURISDICTIONS IN H2 2024
Source text for Eikon: ID:nGNX40pBYH
Further company coverage: ZYME.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zymeworks
See all newsUS STOCKS ON THE MOVE-Huron Consulting, RingCentral, Selective Insurance
U.S. STOCKS ON THE MOVE-Huron Consulting, Crown Castle, Bloom Energy
US STOCKS ON THE MOVE-Booz Allen Hamilton, SLB, Deckers Outdoor
US STOCKS ON THE MOVE-American Express, Gorman-Rupp, Moderna
Zymeworks gains on up to $813 million Roche licensing deal for lung cancer drug